Clinical trialNCT01287936CompletedPhase 1/PHASE2Interventional

A Study of Modified Stem Cells in Stable Ischemic Stroke

SponsorSanBio, Inc.Enrollment18Chronic Ischemic Stroke

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The primary purpose of the clinical study is to determine the safety of a modified stem cell SB623 when administered to chronic, stable ischemic stroke patients. A second purpose is to determine whether SB623 might improve stroke symptoms. Chronic, stable ischemic stroke patients must be between 6 and 60 months after their stroke, and with only this one prior stroke, and with no further improvement from physical therapy.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Gary K Steinberg, M.D., Ph.D.
Stanford University
Principal Investigator
clinicaltrials.gov ↗
James Markert, M.D.
University of Alabama at Birmingham
Principal Investigator
clinicaltrials.gov ↗
Joshua M Rosenow, M.D.,FACS
Northwestern University
Principal Investigator
clinicaltrials.gov ↗
Lawrence R Wechsler, M.D.
University of Pittsburgh Medical Center
Principal Investigator
clinicaltrials.gov ↗
Robert E Gross, M.D., Ph.D.
Emory University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama
Birmingham, Alabama, United States
Stanford University School of Medicine
Stanford, California, United States
Emory University
Atlanta, Georgia, United States
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

SB623

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Jan 2011
Primary completion: 31 Aug 2015
Completion: 31 Aug 2015
Last update posted: 3 Feb 2023
Registered enrollment: 18
Registry id: NCT01287936

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.